Drug intelligence / Profile preview

titanium dioxide nanotubes

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Local/implant-based, Intranasal, Inhalation, Oral

Overview

Titanium dioxide nanotubes (TNT) are a type of nanomaterial investigated for their anticancer properties, particularly in melanoma. They function as an anticancer agent by inducing apoptosis, inhibiting cell proliferation and migration, and causing cell cycle arrest. While often studied in combination with other agents like quercetin to enhance efficacy, titanium dioxide nanotubes themselves demonstrate intrinsic anticancer activity.

Targets

CASP3 (Caspase-3)

Beyond the preview

Go deeper on titanium dioxide nanotubes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on titanium dioxide nanotubes.

Explore the full profile